EdiGene snags about $67m Series B

Beijing-based EdiGene, Inc., a developer of genome editing technologies, has raised about $67 million in Series B financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this